The Cambridgeshire, England-based biopharmaceutical company reported a pretax loss of GBP10.6 million in 2024, widened from GBP8.9 million in 2023. Revenue was GBP5.1 million, up 10% from GBP4.6 ...

Medtronic has secured a green light from the FDA to connect its latest automated insulin pump with its newest continuous ...

Medtronic (NYSE:MDT) announced that the FDA approved its Simplera Sync continuous glucose monitor for use with the.